Company: GANX
Filing Date: 2025-12-03
Form Type: S-8
Source: 0001104659-25-118118
Chunk: 0

Company: Gain Therapeutics, Inc.
Filing Date: 2025-12-03
Form: S-8
Chunk 0
---
<div align='center'>As filed with the Securities and Exchange Commission on December 3, 2025</div>

Registration No. 333-

<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM S-8

REGISTRATION STATEMENT

UNDER THE SECURITIES ACT OF 1933

Gain Therapeutics, Inc.

(Exact name of registrant as specified in its charter)</div>

| Delaware                        |     |         85-1726310 |
| (State or other jurisdiction of 
 incorporation or organization)  |     |   -I.R.S. Employer 
 Identification No. |
| 4800 Montgomery Lane            
 Suite 220                       
 Bethesda, Maryland              |     |              20814 |
| (Address                        
 of Principal Executive Offices) |     |               -Zip 
               Code |

<div align='center'>Gain Therapeutics, Inc. 2022 Equity Incentive Plan

(Full title of the plan)

Gene Mack

Chief Executive Officer

Gain Therapeutics, Inc.

4800 Montgomery Lane

Suite 220

Bethesda, Maryland 20814

(Name and address of agent for service)

Tel: (301) 500-1556

(Telephone number, including area code, of agent for service)

Please send copies of all communications to:

Steven M. Skolnick, Esq.

Lowenstein Sandler LLP

1251 Avenue of the Americas

New York, New York 10020

Tel: (212) 262-6700</div>

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

| Large             
 accelerated filer | ¨ | Accelerated       
 filer             | ¨ |
| Non-accelerated   
 filer             | x | Smaller           
 reporting company | x |
|                   |   | Emerging          
 growth company    | x |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.¨